Please note – you will leave a website owned by MacroGenics, Inc.
MacroGenics is not responsible for any content on the third party website.
Background
Tebotelimab (previously known as MGD013) is an investigational, bispecific DART® molecule designed to independently or coordinately block PD-1 and LAG-3 checkpoint molecules to sustain or restore the function of exhausted T cells for the treatment of cancer. Monoclonal antibodies that target the immune checkpoints Lymphocyte-activation gene 3 (LAG-3) and PD-1 may have enhanced clinical activity when given in combination. Tebotelimab has been engineered to bind PD-1 and LAG-3 concomitantly or independently and disrupt these non-redundant inhibitory pathways to further restore exhausted T-cell function.
Clinical Development
Please refer to our most recent corporate deck on our Events & Presentations page for the latest clinical information available on tebotelimab..
Our Rights
As part of our November 2018 license and collaboration agreement with Zai Lab Limited (Zai Lab), Zai Lab led regional studies evaluating tebotelimab in various indications in Greater China. In November 2023, Zai Lab provided notice of termination of this agreement, effective as of May 2024, whereupon MacroGenics will retain all global rights to tebotelimab.
Clinical Trials
- Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer (NCT04634825)
- Tebotelimab (MGD013) Phase 1 dose expansion study (NCT03219268)
Presentations & Publications
Relevant Publications and Presentations can be found at https://macrogenics.com/publications/.
The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.